Université de Lille, Faculté de Médecine, CHU de Lille, Laboratoire de Virologie EA3610, 59000, Lille, France.
Université d'Abomey-Calavi, Faculté des Sciences et Techniques, Institut des Sciences Biomédicales Appliquées (ISBA), Laboratoire de Biologie et Physiologie Cellulaires, 01 BP 526, Cotonou, Benin.
Acta Diabetol. 2018 Aug;55(8):827-834. doi: 10.1007/s00592-018-1158-3. Epub 2018 May 17.
Enteroviruses, especially coxsackieviruses B (CV-B), have been associated with the pathogenesis of type 1 diabetes (T1D). An anti-CV-B4 neutralizing activity in saliva of T1D patients was previously reported. Our aim was to study the association between the saliva anti-CV-B4 neutralizing activity and immune parameters in T1D patients in comparison with non-diabetic individuals.
Saliva and blood samples were collected from 15 T1D patients and 8 controls. The anti-CV-B4 and anti-poliovirus type 1 (PV-1) activities of saliva and serum samples were determined by a plaque neutralization assay. Quantification of serum cytokines was performed by ELISA and the frequencies of lymphocyte subsets were evaluated using flow cytometry.
The levels of salivary anti-CV-B4 neutralizing activity were higher in T1D patients than in controls (p = 0.02), whereas the serum levels of anti-CV-B4 neutralizing activity and the saliva and serum levels of anti-PV-1 neutralizing activity were not different. The proportions of effector CD4 T cells and CD19 B cells, but not those of CD4 T cells, CD8 T cells and Foxp3 regulatory T cells, were higher in T1D patients than in controls (p = 0.02 and p = 0.01 respectively). Moreover, serum IFN-γ levels were lower in T1D patients compared to controls (p = 0.03) while IL-4 and IL-10 were not different. There was an association between saliva anti-CV-B4 activity, down-regulation of IFN-γ and B cell expansion in peripheral blood of T1D patients.
The association between saliva anti-CV-B4 activity and disturbance of immune system in T1D patients deserves further investigation.
肠道病毒，尤其是柯萨奇病毒 B（CV-B），与 1 型糖尿病（T1D）的发病机制有关。先前有报道称，T1D 患者唾液中存在抗 CV-B4 中和活性。我们的目的是研究 T1D 患者唾液抗 CV-B4 中和活性与免疫参数之间的关系，并与非糖尿病个体进行比较。
收集了 15 例 T1D 患者和 8 例对照者的唾液和血液样本。通过噬斑中和试验测定唾液和血清样本的抗 CV-B4 和抗脊髓灰质炎病毒 1 型（PV-1）活性。通过 ELISA 测定血清细胞因子的定量，通过流式细胞术评估淋巴细胞亚群的频率。
T1D 患者唾液抗 CV-B4 中和活性水平高于对照组（p=0.02），而血清抗 CV-B4 中和活性水平以及唾液和血清抗 PV-1 中和活性水平无差异。T1D 患者效应性 CD4 T 细胞和 CD19 B 细胞的比例高于对照组（p=0.02 和 p=0.01），但 CD4 T 细胞、CD8 T 细胞和 Foxp3 调节性 T 细胞的比例无差异。此外，T1D 患者血清 IFN-γ 水平低于对照组（p=0.03），而 IL-4 和 IL-10 则无差异。T1D 患者唾液抗 CV-B4 活性与 IFN-γ下调和外周血 B 细胞扩增之间存在相关性。
T1D 患者唾液抗 CV-B4 活性与免疫系统紊乱之间的关联值得进一步研究。
